Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
PPAR2265 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A00006 | 35256934 | Acta Pharm Sin B | Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma. | 2021 | Details |
| A00014 | 35254877 | Arch Physiol Biochem | Resveratrol attenuates against high-fat-diet-promoted non-alcoholic fatty liver disease in rats mainly by targeting the miR-34a/SIRT1 axis. | 2022 | Details |
| A00030 | 35250593 | Front Pharmacol | Combined Use of Bicyclol and Berberine Alleviates Mouse Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A00034 | 35249505 | Curr Drug Saf | Pioglitazone, Bladder Cancer and the Presumption of Innocence. | 2022 | Details |
| A00052 | 35242173 | PPAR Res | Role of Apolipoprotein A1 in PPAR Signaling Pathway for Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A00101 | 35219732 | Eur J Pharmacol | mTOR as an eligible molecular target for possible pharmacological treatment of nonalcoholic steatohepatitis. | 2022 | Details |
| A00165 | 35203610 | Biomedicines | Effects of a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator, Pemafibrate, on Metabolic Parameters: A Retrospective Longitudinal Study. | 2022 | Details |
| A00166 | 35203502 | Biomedicines | Impact of Maternal Obesity on Liver Disease in the Offspring: A Comprehensive Transcriptomic Analysis and Confirmation of Results in a Murine Model. | 2022 | Details |
| A00214 | 35182330 | Mol Cell Biochem | Menin regulates lipid deposition in mouse hepatocytes via interacting with transcription factor FoxO1. | 2022 | Details |
| A00223 | 35178098 | Evid Based Complement Alternat Med | A Network Pharmacology Study on the Active Components and Targets of the Radix Ginseng and Radix Bupleuri Herb Pair for Treating Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A00277 | 35154608 | Gastroenterol Hepatol Bed Bench | Assessment of common and differentially expressed proteins between diabetes mellitus and fatty liver disease: a network analysis. | 2021 | Details |
| A00325 | 35134507 | J Nutr Biochem | Green tea extract increases adiponectin and PPAR α levels to improve hepatic steatosis. | 2022 | Details |
| A00333 | 35132345 | Oxid Med Cell Longev | Differentially Expressed Hepatic Genes Revealed by Transcriptomics in Pigs with Different Liver Lipid Contents. | 2022 | Details |
| A00343 | 35127371 | Acta Pharm Sin B | Therapeutic regulation of autophagy in hepatic metabolism. | 2021 | Details |
| A00346 | 35126843 | World J Hepatol | Is there a role of lipid-lowering therapies in the management of fatty liver disease? | 2022 | Details |
| A00384 | 35108315 | PLoS One | Gut microbiota and butyrate contribute to nonalcoholic fatty liver disease in premenopause due to estrogen deficiency. | 2022 | Details |
| A00386 | 35107741 | Mol Biol Rep | Alternate-day fasting alleviates high fat diet induced non-alcoholic fatty liver disease through controlling PPARα/Fgf21 signaling. | 2022 | Details |
| A00390 | 35104757 | Phytomedicine | Seed oil of Rosa roxburghii Tratt against non-alcoholic fatty liver disease in vivo and in vitro through PPARα/PGC-1α-mediated mitochondrial oxidative metabolism. | 2022 | Details |
| A00429 | 35087411 | Front Pharmacol | Aurantio-Obtusin Attenuates Non-Alcoholic Fatty Liver Disease Through AMPK-Mediated Autophagy and Fatty Acid Oxidation Pathways. | 2022 | Details |
| A00430 | 35087037 | Cell Death Dis | Long-term oral administration of an HNF4α agonist prevents weight gain and hepatic steatosis by promoting increased mitochondrial mass and function. | 2022 | Details |
| A00432 | 35086000 | Food Chem | Amelioration action of gastrodigenin rhamno-pyranoside from Moringa seeds on non-alcoholic fatty liver disease. | 2022 | Details |
| A00470 | 35069992 | World J Hepatol | Non-alcoholic fatty liver disease in irritable bowel syndrome: More than a coincidence? | 2021 | Details |
| A00475 | 35068786 | J Clin Exp Hepatol | Safety and Efficacy of Saroglitazar in Nonalcoholic Fatty Liver Patients With Diabetic Dyslipidemia-A Prospective, Interventional, Pilot Study. | 2021 | Details |
| A00482 | 35066087 | J Hepatol | Is it time for chronopharmacology in NASH? | 2022 | Details |
| A00496 | 35061665 | PLoS Biol | Rab2A regulates the progression of nonalcoholic fatty liver disease downstream of AMPK-TBC1D1 axis by stabilizing PPARγ. | 2022 | Details |
| A00497 | 35061559 | Arch Physiol Biochem | Salidroside inhibits insulin resistance and hepatic steatosis by downregulating miR-21 and subsequent activation of AMPK and upregulation of PPARα in the liver and muscles of high fat diet-fed rats. | 2022 | Details |
| A00501 | 35060744 | J Med Chem | Design, Synthesis, and Biological Evaluation of Triazolone Derivatives as Potent PPARα/δ Dual Agonists for the Treatment of Nonalcoholic Steatohepatitis. | 2022 | Details |
| A00504 | 35058782 | Front Pharmacol | TMEM88 Modulates Lipid Synthesis and Metabolism Cytokine by Regulating Wnt/β-Catenin Signaling Pathway in Non-Alcoholic Fatty Liver Disease. | 2022 | Details |
| A00539 | 35052640 | Antioxidants (Basel) | Phytochemicals from the Cocoa Shell Modulate Mitochondrial Function, Lipid and Glucose Metabolism in Hepatocytes via Activation of FGF21/ERK, AKT, and mTOR Pathways. | 2022 | Details |
| A00544 | 35052547 | Antioxidants (Basel) | Preventive Effects of β-Cryptoxanthin, a Potent Antioxidant and Provitamin A Carotenoid, on Lifestyle-Related Diseases-A Central Focus on Its Effects on Non-Alcoholic Fatty Liver Disease (NAFLD). | 2021 | Details |
| A00547 | 35051553 | Mol Cell Endocrinol | Pdcd4 promotes lipid deposition by attenuating PPARα-mediated fatty acid oxidation in hepatocytes. | 2022 | Details |
| A00550 | 35050176 | Metabolites | Lentinan Protects against Nonalcoholic Fatty Liver Disease by Reducing Oxidative Stress and Apoptosis via the PPARα Pathway. | 2022 | Details |
| A00579 | 35041255 | Phytother Res | Activation of PGC-1α via isoliquiritigenin-induced downregulation of miR-138-5p alleviates nonalcoholic fatty liver disease. | 2022 | Details |
| A00595 | 35035496 | Evid Based Complement Alternat Med | Lanzhang Granules Ameliorate Nonalcoholic Fatty Liver Disease by Regulating the PPARα Signaling Pathway. | 2022 | Details |
| A00600 | 35034930 | Biol Pharm Bull | Vitexin Attenuates Non-alcoholic Fatty Liver Disease Lipid Accumulation in High Fat-Diet Fed Mice by Activating Autophagy and Reducing Endoplasmic Reticulum Stress in Liver. | 2022 | Details |
| A00609 | 35030323 | Lancet Gastroenterol Hepatol | Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review. | 2022 | Details |
| A00623 | 35024308 | Acta Pharm Sin B | Proteomics and metabolic phenotyping define principal roles for the aryl hydrocarbon receptor in mouse liver. | 2021 | Details |
| A00651 | 35014161 | Diabetes Obes Metab | The metabolic triad of non-alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: Implications for treatment. | 2022 | Details |
| A00656 | 35013417 | Sci Rep | Different sites of actions make different responses to thiazolidinediones between mouse and rat models of fatty liver. | 2022 | Details |
| A00662 | 35011585 | Cells | Cynanchum atratum Alleviates Non-Alcoholic Fatty Liver by Balancing Lipogenesis and Fatty Acid Oxidation in a High-Fat, High-Fructose Diet Mice Model. | 2021 | Details |
| A00677 | 35005749 | Food Funct | Protective effect of orange essential oil on the formation of non-alcoholic fatty liver disease caused by high-fat diet. | 2022 | Details |
| A00679 | 35005107 | Genes Dis | Critical roles of FTO-mediated mRNA m6A demethylation in regulating adipogenesis and lipid metabolism: Implications in lipid metabolic disorders. | 2021 | Details |
| A00725 | 34988225 | Biomed Res Int | Target Deconvolution of Fenofibrate in Nonalcoholic Fatty Liver Disease Using Bioinformatics Analysis. | 2021 | Details |
| A00726 | 34988202 | Ann Transl Med | Y-box binding protein 1 regulates liver lipid metabolism by regulating the Wnt/β-catenin signaling pathway. | 2021 | Details |
| A00731 | 34986301 | Endocrinol Metab (Seoul) | The Effects of PPAR Agonists on Atherosclerosis and Nonalcoholic Fatty Liver Disease in ApoE-/-FXR-/- Mice. | 2021 | Details |
| A00748 | 34981123 | Biosci Rep | Tandem mass tag-based proteomics analysis of type 2 diabetes mellitus with non-alcoholic fatty liver disease in mice treated with acupuncture. | 2022 | Details |
| A00787 | 34966475 | Oxid Med Cell Longev | Structural and Functional Modulation of Gut Microbiota by Jiangzhi Granules during the Amelioration of Nonalcoholic Fatty Liver Disease. | 2021 | Details |
| A00796 | 34964438 | Elife | Hepatic MIR20B promotes nonalcoholic fatty liver disease by suppressing PPARA. | 2021 | Details |
| A00818 | 34957498 | Diabetes | Hepatic CPT1A Facilitates Liver-Adipose Cross-Talk via Induction of FGF21 in Mice. | 2021 | Details |
| A00831 | 34954593 | Eur J Med Chem | Discovery of new and highly effective quadruple FFA1 and PPARα/γ/δ agonists as potential anti-fatty liver agents. | 2021 | Details |
| A00838 | 34951993 | Gastroenterology | Molecular Signature Predictive of Long-Term Liver Fibrosis Progression to Inform Antifibrotic Drug Development. | 2021 | Details |
| A00851 | 34948020 | Int J Mol Sci | The New Therapeutic Approaches in the Treatment of Non-Alcoholic Fatty Liver Disease. | 2021 | Details |
| A00879 | 34943221 | Biology (Basel) | Beta vulgaris L. (Beetroot) Methanolic Extract Prevents Hepatic Steatosis and Liver Damage in T2DM Rats by Hypoglycemic, Insulin-Sensitizing, Antioxidant Effects, and Upregulation of PPARα. | 2021 | Details |
| A00905 | 34933428 | Zhonghua Gan Zang Bing Za Zhi | [Studying the correlation between ferritin and non-alcoholic fatty liver disease]. | 2021 | Details |
| A00943 | 34923087 | J Ethnopharmacol | Highland barley Monascus purpureus Went extract ameliorates high-fat, high-fructose, high-cholesterol diet induced nonalcoholic fatty liver disease by regulating lipid metabolism in golden hamsters. | 2021 | Details |
| A01024 | 34900534 | Acta Pharm Sin B | Integrative lipidomic and transcriptomic study unravels the therapeutic effects of saikosaponins A and D on non-alcoholic fatty liver disease. | 2021 | Details |
| A01028 | 34898613 | PLoS One | The association between Helicobacter pylori with nonalcoholic fatty liver disease assessed by controlled attenuation parameter and other metabolic factors. | 2021 | Details |
| A01029 | 34897744 | J Appl Toxicol | Fluoxetine-induced hepatic lipid accumulation is mediated by prostaglandin endoperoxide synthase 1 and is linked to elevated 15-deoxy-Δ12,14 PGJ2. | 2021 | Details |
| A01059 | 34884755 | Int J Mol Sci | Role of ANGPTL8 in NAFLD Improvement after Bariatric Surgery in Experimental and Human Obesity. | 2021 | Details |
| A01095 | 34870551 | Pharm Biol | Ellagic acid protects against non-alcoholic fatty liver disease in streptozotocin-diabetic rats by activating AMPK. | 2022 | Details |
| A01108 | 34867358 | Front Pharmacol | (+)-Dehydrovomifoliol Alleviates Oleic Acid-Induced Lipid Accumulation in HepG2 Cells via the PPARα-FGF21 Pathway. | 2021 | Details |
| A01113 | 34866843 | J Clin Exp Hepatol | Role of Diffusion-Weighted Magnetic Resonance Imaging in the Diagnosis and Grading of Hepatic Steatosis in Patients With Non-alcoholic Fatty Liver Disease: Comparison With Ultrasonography and Magnetic Resonance Spectroscopy. | 2021 | Details |
| A01114 | 34866842 | J Clin Exp Hepatol | Adipocytokines as Risk Factors for Development of Nonalcoholic Fatty Liver Disease in Children. | 2021 | Details |
| A01132 | 34860704 | Eur J Gastroenterol Hepatol | Serum copper, ceruloplasmin, and their relations to metabolic factors in nonalcoholic fatty liver disease: a cross-sectional study. | 2022 | Details |
| A01186 | 34836021 | Nutrients | Euphausia pacifica (North Pacific Krill): Review of Chemical Features and Potential Benefits of 8-HEPE against Metabolic Syndrome, Dyslipidemia, NAFLD, and Atherosclerosis. | 2021 | Details |
| A01208 | 34829565 | Antioxidants (Basel) | Anti-NAFLD Effect of Djulis Hull and Its Major Compound, Rutin, in Mice with High-Fat Diet (HFD)-Induced Obesity. | 2021 | Details |
| A01219 | 34825068 | Biochem Biophys Rep | Metformin treatment reverses high fat diet- induced non-alcoholic fatty liver diseases and dyslipidemia by stimulating multiple antioxidant and anti-inflammatory pathways. | 2021 | Details |
| A01220 | 34823548 | J Transl Med | CD226 knockout alleviates high-fat diet induced obesity by suppressing proinflammatory macrophage phenotype. | 2021 | Details |
| A01225 | 34822586 | Toxins (Basel) | Ochratoxin A Induces Steatosis via PPARγ-CD36 Axis. | 2021 | Details |
| A01233 | 34819792 | Saudi Pharm J | Cold-pressed raspberry seeds oil ameliorates high-fat diet triggered non-alcoholic fatty liver disease. | 2021 | Details |
| A01281 | 34803499 | Int J Biol Sci | CD38 Deficiency Protects Mice from High Fat Diet-Induced Nonalcoholic Fatty Liver Disease through Activating NAD+/Sirtuins Signaling Pathways-Mediated Inhibition of Lipid Accumulation and Oxidative Stress in Hepatocytes. | 2021 | Details |
| A01308 | 34794234 | Biomed Pharmacother | Saroglitazar and Hepano treatment offers protection against high fat high fructose diet induced obesity, insulin resistance and steatosis by modulating various class of hepatic and circulating lipids. | 2021 | Details |
| A01342 | 34783017 | Br J Pharmacol | A novel HSF1 activator ameliorates non-alcoholic steatohepatitis by stimulating mitochondrial adaptive oxidation. | 2022 | Details |
| A01378 | 34768942 | Int J Mol Sci | In a Prediabetic Model, Empagliflozin Improves Hepatic Lipid Metabolism Independently of Obesity and before Onset of Hyperglycemia. | 2021 | Details |
| A01435 | 34746842 | Curr Res Physiol | High-fat diet-associated cognitive decline: Is zinc finger protein 1 (ZPR1) the molecular connection? | 2021 | Details |
| A01443 | 34743980 | Eur J Pharmacol | Preventive and therapeutic role of betaine in liver disease: A review on molecular mechanisms. | 2021 | Details |
| A01542 | 34704008 | Metabol Open | Deficiency of SREBP1c modulates autophagy mediated lipid droplet catabolism during oleic acid induced steatosis. | 2021 | Details |
| A01586 | 34684586 | Nutrients | Time-Restricted Feeding during Puberty Ameliorates Adiposity and Prevents Hepatic Steatosis in a Mouse Model of Childhood Obesity. | 2021 | Details |
| A01593 | 34684339 | Nutrients | Ethanol Extract of Liriope platyphylla Root Attenuates Non-Alcoholic Fatty Liver Disease in High-Fat Diet-Induced Obese Mice via Regulation of Lipogenesis and Lipid Uptake. | 2021 | Details |
| A01613 | 34680463 | Biomedicines | Non-Alcoholic Fatty Liver Disease in Lean and Non-Obese Individuals: Current and Future Challenges. | 2021 | Details |
| A01614 | 34679681 | Antioxidants (Basel) | Ameliorative Effect of Annona muricata (Graviola) Extract on Hyperglycemia Induced Hepatic Damage in Type 2 Diabetic Mice. | 2021 | Details |
| A01635 | 34675003 | Diabetes | Hepatic CPT1A Facilitates Liver-Adipose Cross-Talk via Induction of FGF21 in Mice. | 2021 | Details |
| A01645 | 34670042 | N Engl J Med | A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. | 2021 | Details |
| A01652 | 34667947 | JHEP Rep | New targets for NAFLD. | 2021 | Details |
| A01660 | 34664288 | J Food Biochem | Sesamol ameliorates hepatic lipid accumulation and oxidative stress in steatosis HepG2 cells via the PPAR signaling pathway. | 2021 | Details |
| A01673 | 34659439 | Evid Based Complement Alternat Med | Ginsenoside Re Improves Inflammation and Fibrosis in Hepatic Tissue by Upregulating PPARγ Expression and Inhibiting Oxidative Stress in db/db Mice. | 2021 | Details |
| A01687 | 34653759 | Biomed Pharmacother | Effects of DHA dietary intervention on hepatic lipid metabolism in apolipoprotein E-deficient and C57BL/6J wild-type mice. | 2021 | Details |
| A01689 | 34653601 | J Nutr Biochem | Copper (Cu) induced changes of lipid metabolism through oxidative stress-mediated autophagy and Nrf2/PPARγ pathways. | 2021 | Details |
| A01698 | 34651285 | J Physiol Biochem | Astaxanthin attenuates hepatic steatosis in high-fat diet-fed rats by suppressing microRNA-21 via transactivation of nuclear factor erythroid 2-related factor 2. | 2021 | Details |
| A01712 | 34646529 | Food Sci Nutr | Sargassum fusiforme polysaccharide attenuates high-sugar-induced lipid accumulation in HepG2 cells and Drosophila melanogaster larvae. | 2021 | Details |
| A01723 | 34638941 | Int J Mol Sci | MERTK+/hi M2c Macrophages Induced by Baicalin Alleviate Non-Alcoholic Fatty Liver Disease. | 2021 | Details |
| A01725 | 34638640 | Int J Mol Sci | Impact of Dietary Fat on the Progression of Liver Fibrosis: Lessons from Animal and Cell Studies. | 2021 | Details |
| A01758 | 34627976 | J Hepatol | Exposure to environmental contaminants is associated with altered hepatic lipid metabolism in non-alcoholic fatty liver disease. | 2021 | Details |
| A01775 | 34621326 | Evid Based Complement Alternat Med | A Novel Identified Peptide Hormone "Metabolitin" Attenuates Lipid Absorption in the Small Intestine of Diabetic Mice with Nonalcoholic Fatty Liver Disease by Regulating Neurotensin and AMPK Signaling Pathway. | 2021 | Details |
| A01808 | 34607257 | Biochem Biophys Res Commun | The alleviating effect of sphingosine kinases 2 inhibitor K145 on nonalcoholic fatty liver. | 2021 | Details |
| A01811 | 34606980 | Endocr Pract | Antidiabetic Medications for Type 2 Diabetics with Nonalcoholic Fatty Liver Disease: Evidence From a Network Meta-Analysis of Randomized Controlled Trials. | 2021 | Details |
| A01819 | 34604287 | Front Nutr | Transcriptomic Analysis Reveals a Sex-Dimorphic Influence of GAT-2 on Murine Liver Function. | 2021 | Details |
| A01836 | 34600906 | Metabolism | The presence of NAFLD influences the transition of metabolically healthy to metabolically unhealthy obesity and the ten-year cardiovascular disease risk: A population-based cohort study. | 2021 | Details |
| A01843 | 34593018 | BMC Pharmacol Toxicol | Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis. | 2021 | Details |
| A01861 | 34585409 | J Food Biochem | Crataegus aronia prevents high-fat diet-induced hepatic steatosis in rats by activating AMPK-induced suppression of SREBP1 and activation of PPARα. | 2021 | Details |